



## **Prostatype Genomics AB**

Org. 556726-0285

### **Year End Report 2021**

1 January 2021 – 31 December 2021

&

### **Quarterly report**

1 October 2021 – 31 December 2021

## Quarterly report

1 October 2021 – 31 December 2021

&

## Year end report

1 January 2021 – 31 December 2021

### Quarter 4 (1 October – 31 December 2021) summarized

- Net sales amounted to 0 (347) TSEK.
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -5 712 (-4 731) TSEK.
- Cash flow from current operations in the quarter amounted -5 381 (-3 919) TSEK.
- Total cash flow for the period amounted to -6 216 (11 442) TSEK.
- Earnings per share amounted to -0,32 (-0,36) SEK.

### Full year (1 January 2021 – 31 December 2021) summarized

- Net sales amounted to 10 (684) TSEK.
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -15 460 (-15 765) TSEK.
- Cash flow from current operations in the quarter amounted -16 078 (-14 712) TSEK.
- Total cash flow for the period amounted to 4 467 (13 170) TSEK.
- Earnings per share amounted to -1,04 (1,32) SEK.



## Significant events during the Fourth Quarter

### Processing of geographic target markets

Since the listing on Nasdaq First North Growth Market in the autumn of 2020, Prostatype Genomics AB has implemented the defined commercialization strategy by initiating establishment in the geographic target markets of the Nordic countries, Germany, Italy, the United Kingdom and Spain (including Portugal). The company will conduct operations in these markets in collaboration with partners, as well as under its own auspices with key people contracted. In total, these markets are estimated to have an annual potential of SEK 2.9 billion, of which the addressable market for Prostatype Genomics is estimated to amount to SEK 2.2 billion.

Prostatype Genomics intends to establish operations in additional countries in the coming years. Target markets include France, the Benelux countries, the United States, China and the markets in the Middle East and Gulf region.

### Market entry Italy

In Italy, Prostatype Genomics has established operations by contracting Maurizio Ballerini (MD) as Senior Director of Market Development Italy for the company. Ballerini is a medical doctor and has experience working for medical technology companies such as Abbott Diagnostics and Randox with successful results as responsible for sales of PCA3 tests (tests to determine the risk of developing prostate cancer).

### Market entry Germany

In Germany, Prostatype Genomics has established operations by contracting Karlheinz Dewald as Director of Market Development Germany for the company. Dewald has many years of experience from commercial roles in leading companies in areas such as biotechnology, oncology, and urology. Most recently, Dewald led the implementation of a new molecular biomarker for oncological diagnostics and treatment monitoring in Germany, Switzerland, and Austria.

### Extended Lock-up period

In connection with the IPO of Prostatype Genomics, board members as well as management and other shareholders entered into lock-up agreements. These agreements expired on November 3, 2021, which is 12 months after the first day of trading in Prostatype Genomics' shares and warrants on the Nasdaq First North Growth Market.

Both the board and management have entered into extended lock-up agreements until April 30 2022. The parties that have entered into the agreements are Creathor Venture Fund III (SCS) SICAR, Creathor Venture Fund III Parallel (SCS) SICAR, the board members Håkan Englund, Michael Häggman, Anders Lundberg, CEO Fredrik Persson and CFO Michael af Winklerfelt. These shareholders together own approximately 30 percent of the total shares in the Company.

## Significant events during the financial year

### Strengthened market organization

During the quarter, the company strengthened its marketing organization with a new Sales & Marketing Manager Nordics, and a new Communications Director.

### Swiss co-operation

In August, Prostatype Genomics signed a collaboration agreement with Proteomedix AG ("Proteomedix"), a Zurich-based science-driven company with a market approved prostate cancer product. The agreement covers cooperation regarding both marketing and R&D.

### Directed new share issue

In August, the company carried out a directed new share issue that provided the company with approximately SEK 24.7 million. The capital is intended to finance activities carried out within the framework of the collaboration with Proteomedix, as well as accelerated market entry into priority European markets.

### New distributors in Spain and Portugal

In August 2021, Prostatype Genomics entered into an agreement with Eligen Diagnostica and BioPortugal Lda. as the company's distributors in Spain and Portugal. These companies are leading distributors of advanced healthcare solutions in Spain and Portugal and will commercialise Prostatype® on these markets. The agreement runs until 2024.

### New collaboration in the UK, Cambridge Clinical Laboratories

In August, the Company announced that it had entered into a collaboration agreement with the leading British laboratory company Cambridge Clinical Laboratories ("CCL"). CCL will not only offer Prostatype® in its own laboratories but also promote Prostatype® in the United Kingdom and Ireland.

### Study at the Uppsala University Hospital

In August, the Company published the preliminary results from the clinical study that has been conducted at the Uppsala University Hospital under the leadership of Associate Professor Michael Häggman. The study was conducted to show whether results from the use of Prostatype® before decisions on treatment of patients with prostate cancer correspond to the actual aggressiveness of the tumour, as well as the correlation in P-score between index tumour and other cancer areas in the prostate. For both issues, the study indicates high correlation with high statistical significance.

### Liquidity provider

In June, the Company announced the appointment of Sedermera Fondkommission as liquidity provider for the Company's share. The liquidity providing commenced on June 17 2021.

### **New contract manufacturer**

In June, Prostatype Genomics entered into a multiyear agreement with the German company Minerva Biolabs GmbH (“Minerva”) for manufacturing of the Company’s prognostic biomarker Prostatype® RT-qPCR kit. Minerva was established in 1999 and is a spin off from the well renowned Robert-Koch Institute in Berlin. As a result of this cooperation, Prostatype® will be offered in a freeze-dried format.

### **Study in Taiwan**

In March, the Company announced strong results for Prostatype® in the first step of the ongoing validation study in Taiwan. Based on the positive results, the Company has together with its partner entered into Step 2 of the validation study.

### **Launch of PWS**

In March, the Company launched P-score Web Service (PWS), a web-based solution for the calculation of P-score in a user-friendly, efficient, and secure way.

### **Patent in Canada**

In January, the Company announced that the Canadian Intellectual Property Office is intending to grant the Company patent rights for the genetic test Prostatype® in Canada. In June, the patent was granted. The patent “Marker genes for prostate cancer classification” is valid until October 2032.

## **Events after the balance day**

### **Outcome of the exercise of warrants**

On 17 February 2022, the exercise period for Prostatype Genomics AB’s warrant of series TO 1 ended, which was issued in connection with the Company’s issue of units in September 2020. A total of 14,841 warrants of series TO 1 were exercised. Through the warrants of series TO 1, the Company will receive approximately SEK 162 thousand before issue costs. When the new shares are registered with Bolagsverket, the Swedish Companies Registration Office, the total number of shares will amount to 15,103,602 and the share capital will amount to SEK 906,216.12.

### **Presentation at the American Urology Association annual meeting 2022**

The results from the study carried out at the Uppsala University Hospital have been selected for presentation during the AUA, American Urology Association annual meeting 2022, which takes place in New Orleans on 13-16 May.

The purpose of the study, led by Associate Professor Michael Häggman at the Department of Urology, Uppsala University Hospital, was to show whether the results from the use of Prostatype® before treatment decisions for patients with prostate cancer are consistent with the tumour’s actual aggressiveness.

The first question was whether the Prostatype® genetic test and its P-score algorithm are correlated in fusion-led biopsies in relation to operated prostates, so-called prostatectomies. The second question concerned the correlation in gene expression in the index tumour itself in relation to other cancer areas in the prostate.

The preliminary results show a high degree of correlation in the P-score values (0.83-0.84) for both issues, which are also further underlined by the strong statistical significance for both issues ( $p < 0.0001$ ). This means that the test results from the tissue samples with Prostatype® provide the indication that is requested to determine with greater certainty the next step in the treatment of the patient.

The American Urology Association's Congress 2022 is one of the largest and most important gatherings for urologists globally, and Prostatype Genomics is very proud that one of our clinical validation studies with Prostatype<sup>®</sup>, whose preliminary results were communicated in August 2021, has been selected for presentation at Congress. This is an important step for the upcoming launch of Prostatype<sup>®</sup> on the American market.

## Vision

Our vision is that doctors and patients, confronted with diagnosed prostate cancer, have full confidence in their treatment decisions.

## Mission

**Prostatype Genomics'** mission is to make a difference in prostate cancer patients' lives through the discovery and commercialization of transformative tests to guide treatment decisions. We can thereby increase quality of life and peace-of-mind for patients and simultaneously reduce health care costs. **Prostatype Genomics** will achieve this by making **Prostatype®** the global test system of choice for newly diagnosed prostate cancer patients.

## Upcoming milestones 2022

### European commercialisation

- Routine customer sales in Germany, Italy, UK, and Spain
- Commercial network expansion into new markets within the region
- Prostatype patient e-commerce solution launched, first sales in selected key markets

### US expansion initiated

- Legal entity and senior management in place
- Certified laboratory- and commercial partner selected
- LDT (Laboratory Developed Test)-process initiated
- Presentation of results from the Uppsala-study at AUA (American Urology Association), New Orleans, May 2022

### Advanced preparations for entering Asian key markets

- Chinese Pilot study completed and presented
- Taiwan step 2 study completed
- First sales in Taiwan
- Commercial and regulatory roadmap for entering Japan and South Korea in place

## CEO comments

We can now sum up our first year as a listed company and if I can only use one word to describe it, I choose *expansion*. During 2021, we have worked under very tough circumstances due to the pandemic and the difficulties this has entailed regarding access to healthcare stakeholders. It has in several respects been a strange year where we have had to get used to recurring closures and other restrictions. Since our listing on First North 2020, our ambition has been to initiate an international market presence and we have today established ourselves in five new strategic markets. In addition to our Nordic home market, we now also have a market presence in Germany, Italy, the United Kingdom, Spain, and Portugal. While the world has closed down and future plans have been put on hold, Prostatype Genomics has expanded and continued to achieve important milestones for our continued development and expansion. As we are now hopefully seeing the end of the pandemic, the Company is well positioned both commercially and scientifically to take the next big step. On behalf of my colleagues and myself, I am proud what we have accomplished despite these challenging circumstances.

We believe that there is a very clear demand for Prostatype®, as evidenced by the fact that during the year we entered into significant agreements with, among others, the leading British laboratory company Cambridge Clinical Laboratories ("CCL"). CCL not only offers Prostatype® in its own laboratories but also promotes its use in other urological laboratories around the UK and Ireland. We will now place great emphasis on the partners we have established cooperation with in 2021 receiving the support they need to be able to take the sale of Prostatype® further in each local market.

Furthermore, we also notice an increased interest from other markets as well, and I look with confidence at 2022, where our goal is to complete validation studies in southern and northern Europe and the United States. We will put a lot of focus on starting the commercialization of Prostatype® in the U.S. where our strategy is to register Prostatype® as a so-called LDT-product, which is a faster, safer, and more cost-efficient route to market compared with getting the product directly approved by the FDA. Our ambition is also to continue to sign agreements with distributors in Europe, U.S. and Asia.

During the year, we were able to show several strong clinical results regarding Prostatype®, which attracted a great deal of international attention. Both the validation study from Skåne University Hospital as well as the results from the validation study carried out in Taiwan in an Asian population, show that when using Prostatype®, approximately one third of the patients can be reclassified to another risk group compared with current standard methods. The results confirm the clinical benefit of Prostatype® as an advanced decision support in the choice of treatment.

This means first and foremost less suffering for patients, but also more efficient diagnostics and sampling at lower healthcare costs. The clinical study with Prostatype® conducted at the University Hospital in Uppsala has also been selected to be presented at the American Urology Association annual meeting 2022. It is very gratifying that the study has been selected for presentation at one of the world's largest urology congresses. It is an important stamp of quality for Prostatype®, which also strengthens our international presence and continued expansion.

I look forward to working closely with the partners we have established in 2021 and continue to strengthen our commercialization process internationally, with a strong hope of being able to grow our business with increased sales in the coming financial years. In conclusion, I would like to thank employees, external partners, the board and not least our shareholders who contributed to making 2021 an expansive year for Prostatype Genomics. Thanks!

**Fredrik Persson**

**CEO Prostatype Genomics AB**

**Solna February 24 2022**



## Financial information and comments

### Comparison between October-December 2021 and October-December 2020

#### Net sales

Net sales for the Company amounted to 0 (347) TSEK. The company has not yet begun to sell its product in a significant volume; hence sales are as expected.

#### Operating profit/loss

The operation profit/loss for the Company's 4th quarter 2021 amounted to -5 734 (-4 753) TSEK which is a decrease with approximately 21 percent in comparison to prior period. The Company's expenses are mainly in product development, testing and staff.

#### Cash flow from current operations

The cash flow for the 4th quarter amounted to -6 216 (11 441) TSEK. The cash flow from current operations amounted to -5 381 (-3 919) TSEK. The cash flow for the period is in line with the Company's operating expenses.

#### Cash flow from investment activities

The cash flow from investment activities amounted to -735 (-732) TSEK. The Company has continued investing in product development.

#### Cash flow from financing activities

The cash flow from financing activities amounted -100 (16 093) TSEK. Liquid funds as of 31<sup>st</sup> December 2021 amounted to 20 329 (15 862) TSEK.

#### Number of shares

On December 31<sup>st</sup>, 2020, the number of shares was 15 088 761 (13 186 870). Average amount of shares during the 4<sup>th</sup> quarter was 15 088 761.

### Comparison between January 2021 - December 2021 (12 months) and July 2019 – December 2020 (18 months)

#### Net sales

Net sales for the Company amounted to 10 (684) TSEK. The company has not yet begun to sell its product in a significant volume; hence sales are as expected.

#### Operating profit/loss

The operation profit/loss for the period amounted -15 548 (-15 914) TSEK which is an improvement with approximately 2 percent in comparison to prior period. The Company has continued investing in product development and market.

#### Cash flow from current operations

The cash flow for the period amounted -16 078 (-14 712) TSEK. The cash flow for the period is in line with the Company's operating expenses.

#### Cash flow from investment activities

The cash flow from investment activities amounted to till -2 500 (-3 258) TSEK. The Company has continued investing in product development.

#### Cash flow from financing activities

The cash flow from financing activities amounted 23 045 (31 139) TSEK. Liquid funds as of 31<sup>st</sup> December 2021 amounted to 20 329 (15 862) TSEK. The Company carried out a new share issue in August 2021.

#### Number of shares

On December 31<sup>st</sup>, 2021, the number of shares was 15 088 761 (13 186 870). Average amount of shares for the year was 14 137 816.

## Prostatype Genomics business and financial ratios

Amounts in SEK	2021-10-01 2021-12-31	2020-10-01 2020-12-31	2021-01-01 2021-12-31	2019-07-01 2020-12-31* (18 months)
Operating margin	neg	neg	neg	neg
Profit margin	neg	neg	neg	neg
Return on equity	neg	neg	neg	neg
Equity/debt ratio	89%	84%	89%	84%
Equity captial	35 905 840	28 290 359	35 905 840	28 290 359
Cash flow	-6 216 356	11 441 680	4 467 387	13 169 631
Number of shares (end of the period)	15 088 761	13 186 870	15 088 761	13 186 870
Number of shares (average for the period)	15 088 761	11 244 210	14 137 816	6 644 476
Number of shares - full dilution (end of the period)	15 248 632	13 346 741	15 248 632	13 346 741
Earnings per share	-0,32	-0,36	-1,04	-1,32
Diluted earnings per share (end of the period)	-0,31	0,36	-1,02	-1,30
Number of employees (end of the period)	6	5	6	5
Dividend per share	-	-	-	-

\*The period covers 18 months. The Company's financial year was extended.

### Definition of key ratios

Operating margin	Operating profit/loss after deprecation /net sales
Profit margin	Net profit/loss for the year / net sales
Return on equity	Profit/loss before tax / adjusted equity
Equity/debt ratio	Adjusted equity / total assets
Earnings per share	Net profit/loss for the year / number of shares by period closing
Diluted earnings per share (end of the period)	Net profit/loss for the year / (number of shares + warrants by period closing)

## Financial statement

Amounts in SEK	2021-10-01 2021-12-31	2020-10-01 2020-12-31	2021-01-01 2021-12-31	2019-07-01 2020-12-31* (18 months)
Net sales	0	346 605	10 001	683 878
Own work capitalized	735 019	742 902	2 499 641	3 231 665
Other operating income	0	161 151	12 186	721 004
<b>Total revenue</b>	<b>735 019</b>	<b>1 250 658</b>	<b>2 521 828</b>	<b>4 636 548</b>
<b>Operating expenses</b>				
Research and development cost	-610 879	-124 014	-1 488 110	-2 414 232
Other external cost	-2 840 922	-3 855 426	-8 491 058	-9 834 459
Staff cost	-2 990 616	-2 002 047	-7 980 680	-8 136 244
Depreciation, amortization and impairment	-22 121	-22 121	-88 483	-149 052
Other operating expenses	-4 243	-22	-21 762	-16 373
<b>Operating profit/loss</b>	<b>-5 733 762</b>	<b>-4 752 972</b>	<b>-15 548 265</b>	<b>-15 913 812</b>
<b>Income after financial items</b>				
Interest expenses and similar items			-	
Interest expenses and similar items	-19 487	-22 028	-81 493	-1 494 411
<b>Profit/loss after financial items</b>	<b>-5 753 249</b>	<b>-4 775 000</b>	<b>-15 629 758</b>	<b>-17 408 222</b>
<b>Profit or loss before tax</b>	<b>-5 753 249</b>	<b>-4 775 000</b>	<b>-15 629 758</b>	<b>-17 408 222</b>
<b>Total profit/loss for the period</b>	<b>-5 753 249</b>	<b>-4 775 000</b>	<b>-15 629 758</b>	<b>-17 408 222</b>

\*The period covers 18 months. The Company's financial year was extended.

## Balance sheet

(SEK)	2021-12-31	2020-12-31
<b>ASSETS</b>		
<b>Fixed assets</b>		
<i>Intangible assets</i>		
Capitalized development expenditure	18 566 363	16 066 722
Patent	37 175	111 527
<b>Total intangible assets</b>	<b>18 603 538</b>	<b>16 178 249</b>
<i>Property, plant and equipment</i>		
Plant and machinery	0	0
Equipment and tools	14 089	28 220
<b>Total property, plant and equipment</b>	<b>14 089</b>	<b>28 220</b>
<b>Total fixed assets</b>	<b>18 617 627</b>	<b>16 206 469</b>
<b>Current assets</b>		
<i>Inventory</i>		
Finished products	107 520	366 369
Advances to suppliers	74 506	28 578
<b>Total current assets</b>	<b>182 026</b>	<b>394 947</b>
<i>Current receivables</i>		
Accounts receivable	146 573	336 352
Other receivables	502 980	578 467
Prepaid expenses and accrued income	424 429	284 643
<b>Total current receivables</b>	<b>1 073 982</b>	<b>1 199 462</b>
<i>Short-term investments</i>		
Other short-term investments	10 500 000	0
<b>Total short-term investments</b>	<b>10 500 000</b>	<b>0</b>
<i>Cash and bank</i>		
	9 829 175	15 861 788
<b>Total current assets</b>	<b>21 585 183</b>	<b>17 456 196</b>
<b>TOTAL ASSETS</b>	<b>40 202 810</b>	<b>33 662 665</b>

## Balance sheet

(SEK)	2021-09-30	2020-12-31
<b>EQUITY AND LIABILITIES</b>		
<b>Total equity</b>		
<b>Restricted equity</b>		
Share capital	905 326	791 212
New share issue under registration	-	
Development fund	18 566 363	16 066 722
<b>Total restricted equity</b>	<b>19 471 689</b>	<b>16 857 934</b>
<b>Non-restricted equity</b>		
Share premium reserve	130 452 900	107 321 774
Profit/loss brought forward	-98 388 990	-78 481 127
Net profit/loss for the year	-15 629 758	-17 408 222
<b>Total non-restricted equity</b>	<b>16 434 152</b>	<b>11 432 425</b>
<b>Total equity</b>	<b>35 905 840</b>	<b>28 290 359</b>
<b>Long-term liabilities</b>		
Convertible loan	-	
Other debt to credit institutions	866 667	1 066 667
<b>Total long-term liabilities</b>	<b>866 667</b>	<b>1 066 667</b>
<b>Current liabilities</b>		
Debt to credit institutions	400 000	400 000
Accounts payable	1 174 708	1 779 007
Tax liabilities	176 876	55 374
Other current liabilities	212 175	552 325
Accrued liabilities and deferred income	1 466 544	1 518 933
<b>Total current assets</b>	<b>3 430 303</b>	<b>4 305 639</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>40 202 810</b>	<b>33 662 665</b>

## Cash flow statement

(SEK)	2021-10-01 2021-12-31	2020-10-01 2020-12-31	2021-01-01 2021-12-31	2019-07-01 2020-12-31* (18 months)
<b>Operating activities</b>				
Profit after financial items	-5 753 249	-4 775 000	-15 629 758	-17 408 222
Adjustments for items not included in cash flow etc	22 121	22 121	88 483	776 184
<b>Cash flow from operating activities before changes in working capital</b>	<b>-5 731 128</b>	<b>-4 752 879</b>	<b>-15 541 275</b>	<b>-16 632 038</b>
<b>Cash flow from changes in working capital</b>				
Change in inventory	91 927	150 322	212 921	269 053
Change in operating receivables	-317 422	-90 692	125 480	-79 418
Change in operating liabilities	575 286	774 027	-875 336	1 730 472
<b>Cash flow from current operations</b>	<b>-5 381 338</b>	<b>-3 919 221</b>	<b>-16 078 211</b>	<b>-14 711 931</b>
<b>Investment activities</b>				
Acquisition of intangibles	-735 019	-742 900	-2 499 641	-3 231 664
Acquisition of fixed assets	0	10 995	0	-26 195
<b>Cash flow from investment activities</b>	<b>-735 019</b>	<b>-731 905</b>	<b>-2 499 641</b>	<b>-3 257 859</b>
<b>Financing activities</b>				
Paid-in option premium	0	204 165	0	204 165
Net issue liquidity incl. bridge loan	0	15 988 641	23 245 239	27 877 506
Received convertible loans	0	0	0	3 457 750
Amortization	-100 000	-100 000	-200 000	-400 000
<b>Cash flow from financing activities</b>	<b>-100 000</b>	<b>16 092 806</b>	<b>23 045 239</b>	<b>31 139 421</b>
<b>Cash flow for the period</b>	<b>-6 216 356</b>	<b>11 441 680</b>	<b>4 467 387</b>	<b>13 169 631</b>
<b>Opening liquid funds</b>	<b>26 545 531</b>	<b>4 420 109</b>	<b>15 861 788</b>	<b>2 692 157</b>
<b>Closing liquid funds</b>	<b>20 329 175</b>	<b>15 861 789</b>	<b>20 329 175</b>	<b>15 861 788</b>

\*The period covers 18 months. The Company's financial year was extended.

## Changes in equity

### 1 July 2019 – 31 December 2020 (rev)\*

SEK	Share capital	New share issues in progress	Development fund	Share premium reserve	Accumulated profit/loss
Opening balance	1 020 820	640 250	12 835 058	70 602 034	-76 551 680
New share issue	1 072 609	-640 250		42 046 523	
Expenses of the issue				-5 603 362	
Reduction of the share capital	-1 302 217				1 302 217
Option premium				276 579	
Transfer to development fund			3 231 664		-3 231 664
Result for the period					-17 408 222
<b>Closing balance</b>	<b>791 212</b>	<b>0</b>	<b>16 066 722</b>	<b>107 321 774</b>	<b>-95 889 349</b>

### 1 January 2021 – 31 December 2021

SEK	Share capital	New share issues in progress	Development fund	Share premium reserve	Accumulated profit/loss
Opening balance	791 212		16 066 722	107 321 774	-95 889 349
New share issue	114 113			24 610 470	
Expenses of the issue				-1 479 344	
Option premium					
Transfer to development fund			2 499 641		-2 499 641
Result for the period					-15 629 758
<b>Closing balance</b>	<b>905 325</b>	<b>0</b>	<b>18 566 363</b>	<b>130 452 900</b>	<b>-114 018 748</b>

\*The period covers 18 months. The Company's financial year was extended.

## General information

### Company information

Prostatype Genomics AB with organization number 556726-0285 is a limited company registered in Sweden, domiciled in Stockholm. The address is Industrivägen 19, 171 48 Solna. The company is engaged in the research, development and marketing of medical device products.

In this report, Prostatype Genomics AB is called either by its full name or as “the Company”. All figures in the report are in thousands of Swedish kronor (TSEK) if not otherwise specified.

The Company is the result of fifteen years of research into the genomics of prostate cancer. The Company was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market ready product Prostatype® Test System. Prostatype® is a test for diagnosis and prognosis that has been developed to provide the complementary information that is often needed for the selection of the optimal treatment strategy for each patient. The test analyzes the gene expression in cancer cells from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed. Aided by AI (Artificial Intelligence) technology, the gene test of Prostatype Genomics makes it possible to make a better prognosis and to classify the patient’s illness into different risk types. In that way the Company can reduce the risk of over- or under treatment, which in many cases lead to great discomfort for the patient. Prostatype® is today the only gene test for prostate cancer that is available in kit format. The product is also very scalable in terms of volume since the algorithm that forms the basis of the test is delivered through the web-based solution PWS.

### Accounting principles

The year-end report has been prepared in accordance with) BFNAR 2012:1 Årsredovisning och koncernredovisning (K3) issued by the Swedish Accounting Standards Boards (BFN). The accounting policy for the Company complies with applied accounting principles for the most recent published annual report.

### Intangible assets

The Company has performed an impairment test of the intangible assets, which did not show any need for impairment. The value of the intangible assets is of course contingent on the successful sales of the Company’s product.

### Financing

The Board makes the assessment that the cash of the Company is sufficient for the going concern during 2022 but is also looking into the opportunities for further infusions of capital. The Board is continuously evaluating alternatives for raising capital.

### Options program

At the extra General Meeting in June 2020, two options programs to management and staff were approved. Per the day of closing for this report, there were a total of 159 871 options that had been subscribed for, of which 41 856 for Members of the Board, that give the right to subscribe to one share per option in August 2023 at an exercise price of 13.51 SEK.

### Covid-19

Since quarter four of the previous financial year the Company has experienced certain effects from the Covid-19 pandemic, mainly in the form of certain delay of studies as well as difficulties gaining access to health care professionals. During the financial year the effects have been significant, especially for the commercial operations of the Company.

### Related party transactions

During the period from January 1 2021 to December 31 2021, except for what is detailed below, no related party transactions have taken place.

The Company has during the period procured services for in total 1 008 002 SEK from the company SecureAppbox AB, which is a supplier of web-based solutions for P-score. Håkan Englund, Member of the Board of Prostatype Genomics AB, is the Chairman of the Board of SecureAppbox. Håkan Englund has not taken part in the procurement process for these services.

Transactions with related parties have been performed on market terms.

### Profit disposition

The Board is not intending to propose any dividend at the coming General Meeting.



**Risk factors**

For a description of the most significant market- and operational risk, please see the recent prospectus that is published on the Company's web page [www.prostatypegenomics.com](http://www.prostatypegenomics.com) under the heading Investor Relations.

## Other information

### Dates for publication of financial information

Annual Report 2021	2022-05-05
General Meeting 2022	2022-06-02
Q1	2022-05-12
Q2	2022-08-18
Q3	2022-11-10
Q4 & Year-end Report	2023-02-16

This interim report, as well as further information, is available at Prostatype Genomics' web page, [www.prostatypegenomics.com](http://www.prostatypegenomics.com)

### Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, [ca@skmg.se](mailto:ca@skmg.se).

### Review of interim report

This interim report has not been subject to review by the Company's auditors

### Publication

*This information is such information that Prostatype Genomics AB, from the time of listing, is obliged to publish in accordance with the EU market abuse regulation. The information is published by the below contact person, for publication on February 24, 8.00 AM. All information is given also in a Swedish version, and in case of any discrepancies, the Swedish version prevails.*

Fredrik Persson, CEO, +46 73-049 77 01, [fredrik.persson@prostatypegenomics.com](mailto:fredrik.persson@prostatypegenomics.com)

This interim report gives an accurate overview of the Company's operations, financial status, and results.

**Solna, February 24 2022**

---

Anders Lundberg  
Chairman

---

Håkan Englund  
Director

---

Michael Häggman  
Director

---

Karlheinz Schmelig  
Director

---

Fredrik Persson  
CEO



**Prostatype Genomics AB**

Industrivägen 19, SE-171 48 Solna

Telefon:

+46 (0)8-20 87 00

Hemsida:

[www.prostatypegenomics.com](http://www.prostatypegenomics.com)